Merck ready to 'rumble' over pay-for-delay; seeks SCOTUS verdict
This article was originally published in Scrip
Executive Summary
While the rivalry between the prescription drug industry and the US Federal Trade Commission (FTC) over pay-for-delay deals may not be the "Sharks versus Jets" knife fight, Merck, nonetheless, is ready to rumble at the highest court in the US.